Trade Vir Biotechnology, Inc. - VIR CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.09 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026235% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.004012% | ||||||||
Overnight fee time | 22:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Vir Biotechnology Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 9.46 |
Open* | 9.16 |
1-Year Change* | -67.48% |
Day's Range* | 9.13 - 9.66 |
52 wk Range | 7.72-31.55 |
Average Volume (10 days) | 1.63M |
Average Volume (3 months) | 31.05M |
Market Cap | 1.27B |
P/E Ratio | -100.00K |
Shares Outstanding | 134.52M |
Revenue | 118.80M |
EPS | -4.49 |
Dividend (Yield %) | N/A |
Beta | 0.37 |
Next Earnings Date | Feb 21, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Dec 1, 2023 | 9.66 | 0.29 | 3.09% | 9.37 | 9.66 | 9.07 |
Nov 30, 2023 | 9.46 | -0.35 | -3.57% | 9.81 | 10.02 | 9.41 |
Nov 29, 2023 | 9.77 | 0.15 | 1.56% | 9.62 | 9.96 | 9.62 |
Nov 28, 2023 | 9.55 | 0.22 | 2.36% | 9.33 | 9.62 | 9.33 |
Nov 27, 2023 | 9.46 | -0.22 | -2.27% | 9.68 | 9.68 | 9.27 |
Nov 24, 2023 | 9.68 | -0.04 | -0.41% | 9.72 | 10.00 | 9.66 |
Nov 22, 2023 | 9.80 | 0.33 | 3.48% | 9.47 | 9.84 | 9.47 |
Nov 21, 2023 | 9.39 | -0.13 | -1.37% | 9.52 | 9.67 | 9.39 |
Nov 20, 2023 | 9.75 | 0.09 | 0.93% | 9.66 | 9.95 | 9.58 |
Nov 17, 2023 | 9.66 | -0.03 | -0.31% | 9.69 | 9.88 | 9.60 |
Nov 16, 2023 | 9.59 | 0.07 | 0.74% | 9.52 | 9.67 | 9.39 |
Nov 15, 2023 | 9.64 | -0.13 | -1.33% | 9.77 | 10.09 | 9.55 |
Nov 14, 2023 | 9.84 | 0.30 | 3.14% | 9.54 | 9.90 | 9.22 |
Nov 13, 2023 | 9.13 | 0.40 | 4.58% | 8.73 | 9.23 | 8.48 |
Nov 10, 2023 | 8.75 | 0.52 | 6.32% | 8.23 | 8.76 | 8.11 |
Nov 9, 2023 | 8.10 | -0.52 | -6.03% | 8.62 | 8.62 | 8.02 |
Nov 8, 2023 | 8.55 | 0.28 | 3.39% | 8.27 | 8.81 | 8.17 |
Nov 7, 2023 | 8.39 | -0.13 | -1.53% | 8.52 | 8.67 | 8.28 |
Nov 6, 2023 | 8.59 | -0.14 | -1.60% | 8.73 | 8.81 | 8.51 |
Nov 3, 2023 | 8.72 | 0.50 | 6.08% | 8.22 | 9.30 | 8.22 |
Vir Biotechnology, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Wednesday, February 21, 2024 | ||
Time (UTC) 21:00 | Country US
| Event Q4 2023 Vir Biotechnology Inc Earnings Release Q4 2023 Vir Biotechnology Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 1615.8 | 1095.42 | 76.368 | 8.091 | 10.668 |
Revenue | 1615.8 | 1095.42 | 76.368 | 8.091 | 10.668 |
Total Operating Expense | 782.729 | 674.664 | 373.348 | 186.07 | 129.36 |
Selling/General/Admin. Expenses, Total | 161.762 | 160.793 | 70.937 | 37.598 | 29.131 |
Research & Development | 474.148 | 447.506 | 301.411 | 147.272 | 99.129 |
Depreciation / Amortization | 0.5 | 0.5 | 1 | 1.2 | 1.1 |
Unusual Expense (Income) | |||||
Operating Income | 833.068 | 420.751 | -296.98 | -177.979 | -118.692 |
Interest Income (Expense), Net Non-Operating | -83.048 | 138.488 | 2.836 | 8.511 | 2.54 |
Other, Net | 4.26 | -9.437 | -4.467 | -5.061 | -0.212 |
Net Income Before Taxes | 754.28 | 549.802 | -298.611 | -174.529 | -116.364 |
Net Income After Taxes | 515.837 | 528.584 | -298.665 | -174.683 | -115.884 |
Net Income Before Extra. Items | 515.837 | 528.584 | -298.665 | -174.683 | -115.884 |
Net Income | 515.837 | 528.584 | -298.665 | -174.683 | -115.884 |
Income Available to Common Excl. Extra. Items | 515.837 | 528.584 | -298.665 | -174.683 | -115.884 |
Income Available to Common Incl. Extra. Items | 515.837 | 528.584 | -298.665 | -174.683 | -115.884 |
Diluted Net Income | 515.837 | 528.584 | -298.665 | -174.683 | -115.884 |
Diluted Weighted Average Shares | 134.811 | 133.437 | 119.159 | 30.3499 | 109.397 |
Diluted EPS Excluding Extraordinary Items | 3.82637 | 3.9613 | -2.50643 | -5.75563 | -1.0593 |
Diluted Normalized EPS | 3.82637 | 3.9613 | -2.50643 | -5.75563 | -1.0593 |
Total Extraordinary Items | 0 | ||||
Cost of Revenue, Total | 146.319 | 65.865 | |||
Gross Profit | 1469.48 | 1029.55 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 3.797 | 62.957 | 49.41 | 374.557 | -40.629 |
Revenue | 3.797 | 62.957 | 49.41 | 374.557 | -40.629 |
Cost of Revenue, Total | 0.022 | 1.907 | 5.996 | 22.253 | 27.921 |
Gross Profit | 3.775 | 61.05 | 43.414 | 352.304 | -68.55 |
Total Operating Expense | 218.983 | 206.328 | 199.912 | 179.593 | 184.593 |
Selling/General/Admin. Expenses, Total | 47.101 | 46.778 | 38.743 | 43.174 | 41.59 |
Research & Development | 171.86 | 157.643 | 155.173 | 114.166 | 115.082 |
Operating Income | -215.186 | -143.371 | -150.502 | 194.964 | -225.222 |
Interest Income (Expense), Net Non-Operating | 17.93 | 8.204 | 25.051 | -4.258 | -9.19 |
Other, Net | -0.367 | -8.021 | -26.187 | 27.026 | 0.691 |
Net Income Before Taxes | -197.623 | -143.188 | -151.638 | 217.732 | -233.721 |
Net Income After Taxes | -194.775 | -140.956 | -101.603 | 175.312 | -76.493 |
Net Income Before Extra. Items | -194.775 | -140.9 | -101.603 | 175.312 | -76.493 |
Net Income | -194.775 | -140.9 | -101.603 | 175.312 | -76.493 |
Income Available to Common Excl. Extra. Items | -194.775 | -140.9 | -101.603 | 175.312 | -76.493 |
Income Available to Common Incl. Extra. Items | -194.775 | -140.9 | -101.603 | 175.312 | -76.493 |
Diluted Net Income | -194.775 | -140.9 | -101.603 | 175.312 | -76.493 |
Diluted Weighted Average Shares | 134.059 | 133.553 | 133.161 | 134.963 | 132.45 |
Diluted EPS Excluding Extraordinary Items | -1.4529 | -1.05501 | -0.76301 | 1.29896 | -0.57752 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -1.4529 | -1.05501 | -0.76301 | 1.29896 | -0.57752 |
Minority Interest | 0 | 0.056 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 2519.08 | 1562.82 | 772.365 | 402.995 | 117.783 |
Cash and Short Term Investments | 2402.04 | 708.145 | 736.861 | 383.436 | 98.443 |
Cash & Equivalents | 848.631 | 347.815 | 436.575 | 109.335 | 47.598 |
Short Term Investments | 1553.41 | 360.33 | 300.286 | 274.101 | 50.845 |
Prepaid Expenses | 104.356 | 73.003 | 27.511 | 13.378 | 8.579 |
Other Current Assets, Total | 12.681 | 8.594 | 7.993 | 6.181 | 10.761 |
Total Assets | 2802.09 | 1954.27 | 918.761 | 512.071 | 191.596 |
Property/Plant/Equipment, Total - Net | 188.166 | 130.054 | 79.893 | 16.308 | 12.29 |
Property/Plant/Equipment, Total - Gross | 208.909 | 144.546 | 89.125 | 21.14 | 14.006 |
Accumulated Depreciation, Total | -20.743 | -14.492 | -9.232 | -4.832 | -1.716 |
Goodwill, Net | 16.937 | 16.937 | 16.937 | 16.937 | 16.937 |
Intangibles, Net | 32.755 | 33.287 | 33.82 | 35.694 | 36.917 |
Other Long Term Assets, Total | 21.226 | 9.781 | 15.746 | 15.847 | 7.669 |
Total Current Liabilities | 511.029 | 341.242 | 99.064 | 59.206 | 39.908 |
Accounts Payable | 6.422 | 6.521 | 5.077 | 5.881 | 6.473 |
Accrued Expenses | 489.09 | 141.512 | 76.671 | 26.258 | 14.534 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 15.517 | 193.209 | 17.051 | 26.83 | 18.901 |
Total Liabilities | 724.125 | 522.419 | 201.909 | 88.129 | 61.636 |
Total Long Term Debt | 0 | 0 | 0.7 | 0.9 | 0 |
Deferred Income Tax | 3.253 | 18.439 | 3.253 | 3.305 | 3.305 |
Other Liabilities, Total | 209.843 | 162.738 | 98.892 | 24.718 | 18.423 |
Total Equity | 2077.96 | 1431.85 | 716.852 | 423.942 | 129.96 |
Preferred Stock - Non Redeemable, Net | 0 | 309.137 | |||
Common Stock | 0.013 | 0.013 | 0.013 | 0.011 | 0.004 |
Additional Paid-In Capital | 1709.83 | 1571.54 | 1385.3 | 793.051 | 14.669 |
Retained Earnings (Accumulated Deficit) | 377.237 | -138.6 | -667.184 | -368.519 | -193.836 |
Unrealized Gain (Loss) | -9.122 | -1.099 | -1.278 | -0.601 | -0.014 |
Total Liabilities & Shareholders’ Equity | 2802.09 | 1954.27 | 918.761 | 512.071 | 191.596 |
Total Common Shares Outstanding | 133.237 | 131.161 | 127.417 | 107.649 | 109.397 |
Long Term Investments | 23.927 | 201.388 | 24.29 | ||
Current Port. of LT Debt/Capital Leases | 0.265 | 0.237 | |||
Capital Lease Obligations | 0.7 | 0.9 | |||
Total Receivables, Net | 0 | 773.079 | |||
Accounts Receivable - Trade, Net | 0 | 773.079 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 1769.18 | 1946.33 | 2358.63 | 2519.08 | 2413.62 |
Cash and Short Term Investments | 1696.55 | 1847.43 | 2250.07 | 2402.04 | 2346.48 |
Cash & Equivalents | 452.1 | 666.949 | 824.913 | 848.631 | 963.735 |
Short Term Investments | 1244.45 | 1180.48 | 1425.16 | 1553.41 | 1382.75 |
Total Receivables, Net | 0 | 0 | |||
Accounts Receivable - Trade, Net | 0 | 0 | |||
Prepaid Expenses | 59.43 | 85.736 | 97.602 | 104.356 | 54.18 |
Other Current Assets, Total | 13.193 | 13.163 | 10.957 | 12.681 | 12.955 |
Total Assets | 2044.9 | 2243.87 | 2665.94 | 2802.09 | 2695.97 |
Property/Plant/Equipment, Total - Net | 171.931 | 179.06 | 185.263 | 188.166 | 184.942 |
Property/Plant/Equipment, Total - Gross | 201.58 | 204.959 | 211.512 | 208.909 | 203.866 |
Accumulated Depreciation, Total | -29.649 | -25.899 | -26.249 | -20.743 | -18.924 |
Goodwill, Net | 16.937 | 16.937 | 16.937 | 16.937 | 16.937 |
Intangibles, Net | 25.457 | 25.59 | 32.622 | 32.755 | 32.888 |
Other Long Term Assets, Total | 21.777 | 23.597 | 23.293 | 21.226 | 13.485 |
Total Current Liabilities | 165.05 | 225.623 | 485.288 | 511.029 | 308.203 |
Accounts Payable | 3.627 | 12.362 | 12.149 | 6.422 | 2.722 |
Accrued Expenses | 146.111 | 197.58 | 455.922 | 489.09 | 282.616 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 15.312 | 15.681 | 17.217 | 15.517 | 22.865 |
Total Liabilities | 369.81 | 433.666 | 695.179 | 724.125 | 546.115 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Deferred Income Tax | 3.253 | 3.253 | 18.439 | ||
Other Liabilities, Total | 204.76 | 208.043 | 206.594 | 209.843 | 219.473 |
Total Equity | 1675.08 | 1810.21 | 1970.76 | 2077.96 | 2149.85 |
Common Stock | 0.013 | 0.013 | 0.013 | 0.013 | 0.013 |
Additional Paid-In Capital | 1798.82 | 1771.54 | 1737.63 | 1709.83 | 1682.88 |
Retained Earnings (Accumulated Deficit) | -121.851 | 41.562 | 236.337 | 377.237 | 478.84 |
Unrealized Gain (Loss) | -1.9 | -2.903 | -3.219 | -9.122 | -11.88 |
Total Liabilities & Shareholders’ Equity | 2044.9 | 2243.87 | 2665.94 | 2802.09 | 2695.97 |
Total Common Shares Outstanding | 134.498 | 134.23 | 133.931 | 133.237 | 133.027 |
Long Term Investments | 39.617 | 52.358 | 49.187 | 23.927 | 34.102 |
Minority Interest | 0.044 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | 515.837 | 528.584 | -298.665 | -174.683 | -115.884 |
Cash From Operating Activities | 1663.25 | -47.589 | -190.941 | -129.632 | -94.096 |
Cash From Operating Activities | 6.251 | 5.278 | 4.4 | 3.294 | 1.618 |
Amortization | 0.532 | 0.533 | 1.042 | 1.223 | 1.138 |
Deferred Taxes | -15.186 | 15.186 | -0.052 | -0.48 | |
Non-Cash Items | 490.452 | 31.224 | 72.812 | 32.33 | 7.018 |
Changes in Working Capital | 665.367 | -628.394 | 29.522 | 8.204 | 12.494 |
Cash From Investing Activities | -1193.46 | -140.814 | -9.862 | -256.158 | -60.441 |
Capital Expenditures | -68.028 | -21.817 | -6.549 | -8.94 | -9.935 |
Other Investing Cash Flow Items, Total | -1125.43 | -118.997 | -3.313 | -247.218 | -50.506 |
Cash From Financing Activities | 34.761 | 100.331 | 529.474 | 449.244 | 24.978 |
Financing Cash Flow Items | -1.197 | 0 | -4.248 | 10.14 | |
Issuance (Retirement) of Stock, Net | 36.218 | 100.59 | 533.972 | 444.872 | 14.838 |
Net Change in Cash | 504.553 | -88.072 | 328.671 | 63.454 | -129.559 |
Issuance (Retirement) of Debt, Net | -0.26 | -0.259 | -0.25 | 4.372 | |
Cash Taxes Paid | 252.03 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -140.956 | 515.837 | 617.44 | 442.128 | 518.621 |
Cash From Operating Activities | -125.782 | 1663.25 | 1628.13 | 1510.22 | 550.089 |
Cash From Operating Activities | 5.505 | 6.251 | 4.431 | 2.882 | 1.419 |
Amortization | 0.133 | 0.532 | 0.399 | 0.266 | 0.133 |
Non-Cash Items | -1.189 | 490.452 | 470.308 | 474.401 | 26.002 |
Changes in Working Capital | 10.725 | 665.367 | 535.549 | 590.548 | 3.914 |
Cash From Investing Activities | 98.079 | -1193.46 | -1040.33 | -377.721 | -105.392 |
Capital Expenditures | -6.867 | -68.028 | -55.432 | -36.439 | -15.841 |
Other Investing Cash Flow Items, Total | 104.946 | -1125.43 | -984.894 | -341.282 | -89.551 |
Cash From Financing Activities | 2.344 | 34.761 | 32.75 | 30.765 | 27.685 |
Issuance (Retirement) of Stock, Net | 2.31 | 36.218 | 34.13 | 32.086 | 28.946 |
Issuance (Retirement) of Debt, Net | -0.066 | -0.26 | -0.183 | -0.124 | -0.064 |
Net Change in Cash | -25.359 | 504.553 | 620.551 | 1163.27 | 472.382 |
Financing Cash Flow Items | 0.1 | -1.197 | -1.197 | -1.197 | -1.197 |
Deferred Taxes | -15.186 | ||||
Cash Taxes Paid | 252.03 | 191.653 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
SB Investment Advisers (UK) Limited | Investment Advisor | 12.4275 | 16684041 | -494544 | 2023-06-30 | LOW |
ARCH Venture Partners | Venture Capital | 9.6213 | 12916663 | 3377479 | 2022-09-09 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 9.3355 | 12533053 | 204415 | 2023-06-30 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 7.6164 | 10225068 | -28854 | 2023-06-30 | LOW |
GSK plc | Corporation | 6.3694 | 8550954 | 0 | 2023-04-03 | LOW |
Scangos (George A) | Individual Investor | 4.2902 | 5759638 | -1750000 | 2023-10-17 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 4.0363 | 5418804 | 34641 | 2023-06-30 | LOW |
Temasek Holdings Pte. Ltd. | Sovereign Wealth Fund | 3.8239 | 5133610 | -681362 | 2023-06-30 | LOW |
Baillie Gifford & Co. | Investment Advisor | 2.9672 | 3983445 | -2581 | 2023-06-30 | LOW |
AllianceBernstein L.P. | Investment Advisor/Hedge Fund | 2.0497 | 2751716 | 2871 | 2023-06-30 | LOW |
Perceptive Advisors LLC | Private Equity | 1.4587 | 1958264 | 1816070 | 2023-06-30 | MED |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.2594 | 1690777 | 165359 | 2023-06-30 | LOW |
Bill & Melinda Gates Foundation | Foundation | 1.1614 | 1559142 | 0 | 2023-06-30 | LOW |
American Century Investment Management, Inc. | Investment Advisor/Hedge Fund | 1.1021 | 1479560 | 116067 | 2023-06-30 | LOW |
Avidity Partners Management LP | Hedge Fund | 1.0614 | 1425000 | -215200 | 2023-06-30 | HIGH |
Sato (Vicki Lee) | Individual Investor | 0.9798 | 1315351 | -18000 | 2023-06-30 | LOW |
Renaissance Technologies LLC | Hedge Fund | 0.8701 | 1168100 | 7600 | 2023-06-30 | HIGH |
Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.7618 | 1022739 | 977639 | 2023-06-30 | LOW |
Paradigm BioCapital Advisors LP | Investment Advisor | 0.7555 | 1014239 | 1014239 | 2023-06-30 | MED |
Walleye Capital LLC | Hedge Fund | 0.6431 | 863380 | 863380 | 2023-06-30 | HIGH |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Vir Biotechnology Company profile
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products for the treatment and prevention of serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus, and VIR-2020 for the prevention of tuberculosis. The company has grant agreement with Bill & Melinda Gates Foundation and National Institutes of Health; option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; collaboration and license agreement Alnylam Pharmaceuticals, Inc.; collaboration, license, and option agreement Visterra, Inc.; license agreement with The Rockefeller University and MedImmune, Inc.; and collaboration with WuXi Biologics and Alnylam Pharmaceuticals, Inc. The company has a research collaboration agreement with the National Institutes of Health, the National Institute of Allergy and Infectious Diseases, and Vaccine Research Center to advance characterization and development of human monoclonal antibodies against coronaviruses. It operates in the United States, Oregon, Massachusetts, and Switzerland. The company was founded in 2016 and is headquartered in San Francisco, California.Industry: | Biotechnology & Medical Research (NEC) |
1800 Owens Street
Suite 900
SAN FRANCISCO
CALIFORNIA 94158
US
Income Statement
- Annual
- Quarterly
News

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
12:39, 30 November 2023
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023
UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?
UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.
10:48, 21 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com